Effect of 3 Years of Exercise on Development of Atrial Fibrillation
This is a substudy of "Generation 100". In that study, 4000 healthy persons between 70 and 75 will be randomised do moderate intensity, high intensity or control group, with 3 years of exercise. The investigators will follow these persons and register all who develop atrial fibrillation during these 3 years, and at follow-up after ended intervention to see if there is differences in the number of persons who develop atrial fibrillation in the 3 groups.
Behavioral: High intensity exercise
Behavioral: Moderate intensity exercise
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Effect of 3 Years of Exercise on Development of Atrial Fibrillation - A "Generation 100" Substudy|
- Number of persons who develop atrial fibrillation during the 3 year intervention period [ Time Frame: 3 years ] [ Designated as safety issue: No ]People who already have the diagnosis before randomisation will not be counted.
- Number of persons who develop atrial fibrillation during the 6 years after randomisation [ Time Frame: 6 years ] [ Designated as safety issue: No ]
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||December 2025|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: High intensity exercise
High intensity exercise(Borg 16) in intervals.
|Behavioral: High intensity exercise|
Experimental: Moderate intensity exercise
Moderate intensity exercise 3 times a week.
|Behavioral: Moderate intensity exercise|
Experimental: Control group
Exercise on their own. Follow current guidelines.
Advised to follow current guidelines for physical activity, but exercise on their own.
|Contact: Vegard Malmofirstname.lastname@example.org|
|Norwegian University of Science and Technology||Recruiting|
|Trondheim, Norway, 7491|
|Sub-Investigator: Vegard Malmo|
|Study Chair:||Jan Paal Loennechen, PhD||St. Olavs Hospital|